IL1B and myocardial infarction: In the CANTOS study, which was conducted on patients with a history of myocardial infarction, the administration of monoclonal antibodies to IL-1β (Canakinumab) resulted in fewer adverse cardiovascular events relative to patients receiving a placebo [66].